• Explore /
  • Poster
  • / Phase 1/2 study of the activin receptor-like kinase (ALK)-2 inhibitor zilurgisertib (INCB000928, LIMBER-104) as monotherapy or with ruxolitinib (RUX) in patients (pts) with anemia due to myelofibrosis (MF).

Phase 1/2 study of the activin receptor-like kinase (ALK)-2 inhibitor zilurgisertib (INCB000928, LIMBER-104) as monotherapy or with ruxolitinib (RUX) in patients (pts) with anemia due to myelofibrosis (MF).

Abstract Video & Slides Poster

Authors

null

Prithviraj Bose

The University of Texas MD Anderson Cancer Center, Houston, TX

Prithviraj Bose , Sanjay Mohan , Stephen Oh , Jason R. Gotlib , Ellen K. Ritchie , Taizo Shimomura , Haris Ali , Francoise Boyer , Paola Guglielmelli , Anthony Hunter , Betty Lamothe , Yi Cui , Francis Seguy , Amanda McBride , Francesca Palandri , Masahiro Takeuchi , Jean-Jacques Kiladjian

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Track

Hematologic Malignancies

Sub Track

Myeloproliferative Neoplasms (MPN) and Mast Cell Disorders

Clinical Trial Registration Number

NCT04455841

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 7017)

DOI

10.1200/JCO.2023.41.16_suppl.7017

Abstract #

7017

Poster Bd #

147

Abstract Disclosures

Similar Posters

First Author: Haris Ali

First Author: Francesco Passamonti

First Author: Lucia Masarova

First Author: Justin M. Watts